Sign in
Click here - to use the wp menu builder
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Monday, December 23, 2024
Sign in / Join
Facebook
Instagram
Twitter
Vimeo
Youtube
Pharma Deals
Update
Oncology
Search
Tags
Merck&Co.
Tag:
Merck&Co.
Oncology
Merck Announced Discontinuation of Phase 3 KeyVibe-010 Trial Investigating Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
pharmaquotient.com
-
13 May 2024
0
Business Strategy
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
pharmaquotient.com
-
8 May 2024
0
Clinical update
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or...
pharmaquotient.com
-
1 May 2024
0
Merger & Acquisition
Merck Acquired Harpoon Therapeutics, Inc.
pharmaquotient.com
-
11 March 2024
0
Most Read
Neuralink’s Blindsight: A Breakthrough in Vision Restoration
20 September 2024
Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025
17 September 2024
Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.
9 September 2024
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
7 September 2024